Search Results - %22Life+Science%22+and+%22Therapeutics%22

10 Results

Sort By:

Discovery of Well Defined Sulfated Glycopolymers as Specific Heparanase Inhibitors for Cancer Therapeutics

The remodeling of the extracellular matrix has been shown to be highly upregulated in cancer and inflammation and is critically linked to the processes of invasion and metastasis. The finding that heparanase is elevated in a wide variety of tumor types and is subsequently linked to the development of pathological processes has led to an explosion of...

Published: 12/2/2020 | Inventor(s): Hein Nguyen, Ravi Loka, Eric Sletten, Israel Vlodavsky

Keywords(s): Cancer, Cancer Therapies, Pharmaceuticals, Therapeutics

Category(s): Life Science, Oncology, Pharmaceuticals, Therapeutics

Identification of Galeterone's mechanism of action leading to novel treatment therapies for castrate resistant prostate cancer (CRPC)

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (HRPC), is a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT). The need for effective therapies for these difficult to treat cancers is gaining prominence in the prostate cancer market. The global CRPC market is poised...

Published: 4/16/2025 | Inventor(s): Qingping Dou, Huanjie Yang, Elisabeth Heath

Keywords(s):

Category(s): Life Science, Oncology, Pharmaceuticals, Receptors/targets, Process/Procedure, Small molecule, Therapeutics

Drugs that disrupt interactions between ELK1 and the androgen receptor to suppress growth of both early stage and castration resistant prostate cancer

Background:Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, continued disease progression generally represents a transition to the lethal variant. In...

Published: 10/22/2019 | Inventor(s): Manohar Ratnam, Rayna Rosati, Mugdha Patki

Keywords(s):

Category(s): Life Science, Therapeutics, Oncology, Drug Discovery, Pharmaceuticals

Using nanotechnology to target aggressive cancers with a novel small molecule inhibitor of the DNA damage tolerance pathway

Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small molecule...

Published: 8/29/2018 | Inventor(s): Malathy Shekhar, Guangzhao Mao, Yanhua Zhang

Keywords(s):

Category(s): Life Science, Oncology, Small molecule, Receptors/targets, Nano-based, Drug Delivery, Therapeutics, Diseases

SH80 Combinations

BackgroundSH35/SH80 evolved from an effort to improve upon the anti-tumor activity of XK469. XK469 is a compound, currently in Phase 1 clinical trials. The clinical trials include patients with bladder, breast, colorectal, esophageal, head and neck, kidney, liver, lung, mesothelioma, pancreas and sarcoma cancers. Moving a chlorine atom from one position...

Published: 3/2/2022 | Inventor(s): Lisa Polin

Keywords(s): Anti-cancer, Compound

Category(s): Life Science, Oncology, Therapeutics

Targeted Drug Delivery for Spinal Cord Injury

Technology Summary: WSU researchers have developed a new nanoparticle-drug conjugate for treating cervical spinal cord injury (SCI) that can restore respiratory function to the paralyzed hemi diaphragm. Using the nano-conjugate enables targeted delivery of the drug directly to the respiratory centers resulting in dramatically lower effective dosages...

Published: 11/11/2021 | Inventor(s): Harry Goshgarian, Guangzhao Mao, Yi Zou, Sunxi Wang

Keywords(s): Central Nervous System, Drug Delivery, Neuroscience, Therapeutics

Category(s): Therapeutics, Life Science, Drug Delivery, Medical, Chemical Processing/Systhesis, Nanomaterials, Neurological disorders, Receptors/targets

A method to identify patients at risk for subsequent stillbirth in the third trimester

A Method to Identify and Treat Patients at Risk for Stillbirth in the 3rd TrimesterWSU Tech#: 12-1113Technology Summary: This invention is a method of identifying patients at risk for subsequent stillbirth (only due to placental related disorder) in the third trimester using a maternal blood sample. A blood sample would be obtained at the beginning...

Published: 1/12/2022 | Inventor(s): Tinnakorn Chaiworapongsa, Roberto Romero, Sonia Hassan

Keywords(s):

Category(s): Medical, Diagnostic, Prenatal, Small molecule, Specialty compounds, Therapeutics, Life Science

New Methods for the Treatment and Prevention of Preterm Labor

PRODUCT/SERVICE ‘SOLUTION’ DESCRIPTION Pre-term birth (delivery before 37 weeks of gestation) is a serious health problem in the US. and the world, representing a leading cause of infant death and long-term illnesses. Pre-term birth accounts for nearly 11% of all births and 17% of all infant deaths in the U.S., costing >$25 billion...

Published: 2/8/2022 | Inventor(s): Kang Chen

Keywords(s):

Category(s): Prenatal, Therapeutics, Life Science

Antibacterial activity of natural compounds and their synthetic analogue: A potential new antibiotic with potent activity against multiple drug resistant bacterial pathogens

Our researchers have developed novel compounds that are potential new anti-infective therapeutics useful for treatment against the deadly bacteria MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant Enterococcus faecium), and several other well-known common infectious agents.Background & Unmet Need:Before antibiotics became...

Published: 8/9/2022 | Inventor(s): Hossein Salimnia, Fazlul Sarkar, Subhash Padhye, Bernhard Biersack

Keywords(s): Analog or Analogue, Antibiotics, Anti-infective, Anti-microbial, Disease

Category(s): Biologicals, Diseases, Infectious disease, Life Science, Therapeutics

A Diagnostic Marker for Matrix Metalloprotease (MMP)-2 and -9 Activity in Cancer Tissue

This invention is a new and simple method for the identification of active versus latent matrix metalloprotease enzymes (MMPs) in tissue. Background & Unmet Need: MMPs are involved in tumor progression and therefore are targets for anti-cancer drug therapies. However, most drug therapies directed at inhibition of MMPs have failed because there...

Published: 11/22/2021 | Inventor(s): Avraham Raz, Rafael Fridman, Pratima Nangia-Makker

Keywords(s): Biomarker, Cancer, Diagnostics, Enzyme, Method

Category(s): Life Science, Oncology, Research tools, Antibodies, Therapeutics, Diseases